These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 4794659)

  • 1. [Research on the inhibitory action of several salicylic chalcones on the aromatic L-aminoacid-decarboxylase].
    Lesieur-Demarquilly I; Mizon J; Osteux R
    Ann Pharm Fr; 1973 Nov; 31(11):705-8. PubMed ID: 4794659
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pharmacology of several aromatic amino acid decarboxylase inhibitors].
    Uspenskiĭ AE; Dabagov NS; Skoldinov AP
    Biull Eksp Biol Med; 1978 Oct; 86(10):444-7. PubMed ID: 309344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro inhibition of dopa decarboxylase by 6-alkyl derivatives of 3-(3,4-dihydroxyphenyl)alanine (dopa).
    Morgenstern AP; Nauta WT
    Arzneimittelforschung; 1972 Oct; 22(10):1766-8. PubMed ID: 4677070
    [No Abstract]   [Full Text] [Related]  

  • 4. Reduction of aromatic L-amino acid decarboxylase protein in rats after chronic administration of alpha-methyldopa.
    Culvenor AJ; Jarrott B
    Mol Pharmacol; 1979 Jan; 15(1):86-98. PubMed ID: 106235
    [No Abstract]   [Full Text] [Related]  

  • 5. [Endogenous 3-O-methyldopa in man: normal level and effect of an inhibitor of aromatic amino-acid decarboxylase (Benserazid) (author's transl)].
    Geissbühler F; Raffin Y; Combépine C; Streiff U; Hovaguimian T
    J Clin Chem Clin Biochem; 1978 Jun; 16(6):355-8. PubMed ID: 670902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of different dopa decarboxylase inhibitors on the hypotensive response to alpha-methyldopa in rats.
    Henning M
    Br J Pharmacol; 1968 Sep; 34(1):233P-234P. PubMed ID: 5676035
    [No Abstract]   [Full Text] [Related]  

  • 7. DOPA decarboxylase activity in the nervous system and the ctenidium of the freshwater clam, Musculium (Sphaerium) transversum.
    Paparo AA; Murphy JA; Dean RC
    Comp Biochem Physiol C Comp Pharmacol Toxicol; 1984; 77(1):55-7. PubMed ID: 6141881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural insight into Parkinson's disease treatment from drug-inhibited DOPA decarboxylase.
    Burkhard P; Dominici P; Borri-Voltattorni C; Jansonius JN; Malashkevich VN
    Nat Struct Biol; 2001 Nov; 8(11):963-7. PubMed ID: 11685243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mode of action of -methyldopa.
    Day MD; Roach AG; Whiting RL
    Br J Pharmacol; 1972 May; 45(1):168P-169P. PubMed ID: 5041485
    [No Abstract]   [Full Text] [Related]  

  • 10. Site of action of methyldopa in lowering the blood pressure in man.
    Kersting F; Reid JL; Dollery CT
    Clin Exp Pharmacol Physiol Suppl; 1978; 4():11-5. PubMed ID: 277299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aromatic amino acid decarboxylase inhibitors.
    Porter CC
    Fed Proc; 1971; 30(3):871-6. PubMed ID: 5575298
    [No Abstract]   [Full Text] [Related]  

  • 12. Dopa decarboxylase from visceral ganglion and gill of two lamellibranch mollusca as it relates to ciliary activity.
    Paparo AA; Tate SS
    Comp Gen Pharmacol; 1973 Dec; 4(16):383-91. PubMed ID: 4788788
    [No Abstract]   [Full Text] [Related]  

  • 13. The role of brain 5-hydroxytryptamine in the central action of L-DOPA.
    Maj J; Pawlowski L; Sarnek J
    Adv Biochem Psychopharmacol; 1974; 10():253-6. PubMed ID: 4846541
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of the adrenergic system in the action of L-DOPA on brain serotonin.
    Algeri S; Cerletti C
    Adv Biochem Psychopharmacol; 1974; 10():257-9. PubMed ID: 4846542
    [No Abstract]   [Full Text] [Related]  

  • 15. [STUDIES ON THE STEREOSPECIFICITY OF THE DECARBOXYLASE INHIBITING ACTION OF ALPHA-METHYLDOPA].
    PUETTER J; KRONEBERG G
    Naunyn Schmiedebergs Arch Exp Pathol Pharmakol; 1964 Nov; 249():470-8. PubMed ID: 14335181
    [No Abstract]   [Full Text] [Related]  

  • 16. The parkinsonian neurotoxin 1-methyl-4-phenylpyridinium (MPP(+)) mediates release of l-3,4-dihydroxyphenylalanine (l-DOPA) and inhibition of l-DOPA decarboxylase in the rat striatum: a microdialysis study.
    Foster SB; Wrona MZ; Han J; Dryhurst G
    Chem Res Toxicol; 2003 Oct; 16(10):1372-84. PubMed ID: 14565778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment.
    Silva MA; Mattern C; Häcker R; Tomaz C; Huston JP; Schwarting RK
    Synapse; 1997 Dec; 27(4):294-302. PubMed ID: 9372552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapy of parkinsonian syndromes and plasmatic DOPA levels. Effects of L-DOPA and 3-OMD, administered alone or combined, with or without a decarboxylase inhibitor].
    Geissbühler F; Gaillard JM; Eisenring JJ; Krassoievitch M; Yanniotis G; Tissot R
    Rev Eur Etud Clin Biol; 1972 Jan; 17(1):38-44. PubMed ID: 5041348
    [No Abstract]   [Full Text] [Related]  

  • 19. Modification of the cardiovascular effects of L-dopa by decarboxylase inhibitors.
    Watanabe AM; Parks LC; Kopin IJ
    J Clin Invest; 1971 Jun; 50(6):1322-8. PubMed ID: 5578236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An abnormal reaction occurring in the presence of L-aromatic aminoacid decarboxylase.
    Barboni E; Voltattorni CB; D'Erme M; Fiori A; Minelli A; Rosei MA; Turano C
    Biochem Biophys Res Commun; 1981 Mar; 99(2):576-83. PubMed ID: 7236285
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.